Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix (OTCQB: HMTXF) is expanding patient access to its autologous angiogenic-cell therapy ACP-01 in Florida under Senate Bill 1768, which allows licensed physicians to deliver unapproved stem-cell–based treatments for pain and wound care with safety and consent safeguards. The company has deployed a Florida field team, run webinars since August, and will present Grand Rounds at the University of Florida on November 12, 2025.
Key activities include physician training, streamlined compassionate-use access for Rutherford 4–5 CLTI patients, IRB review for a Basket trial, and patient education materials.
Hemostemix (OTCQB: HMTXF) will host a one-hour educational webinar for Florida vascular surgeons on October 29, 2025 at 12:00 PM ET to review ACP-01 (VesCell), an autologous blood-derived stem cell therapy for no-option chronic limb-threatening ischemia (CLTI).
The session covers ACP-01 science, patient qualification (Rutherford class 4-5 with non-healing ulcers), outpatient administration protocol, Florida compassionate-use pathways (Statute s. 381.985), certification steps, clinical outcomes, and a live Q&A. Attendees receive downloadable screening tools and compliance checklists. Registration: https://streamyard.com/watch/wUA8bPj2cN8w; inquiries: clawrence@hemostemix.com.
Hemostemix (OTCQB: HMTXF) announced that Japan granted registration of the trademark "KNOW YOUR HEALTH" under International Registration No. 1744775 on October 22, 2025, covering Classes 1, 5, and 42.
The registration, issued via the Japanese Patent Office through the WIPO Madrid System, secures brand rights for stem-cell preparations, pharmaceutical/biological compositions including autologous ACP-01 uses, and scientific/clinical services in regenerative medicine. The company says this strengthens its IP position in Japan, aligns the mark with ongoing ACP-01 clinical/special-access programs for ischemic and cardiopulmonary indications, and supports licensing and collaboration opportunities in Japan's research market.
Hemostemix (OTCQB: HMTXF) completed a Phase 1 basket-trial protocol titled Treatment of Refractory Angina with Angiogenic Cell Precursors (ACP-01) dated October 15, 2025. The multi-center, open-label, non-randomized study will enroll 20–100 adults aged 40–90 with refractory severe angina to assess feasibility and safety after intracoronary ACP-01 delivery in an outpatient catheterization setting.
Secondary endpoints include chest-pain frequency, six-minute-walk distance, QoL and Karnofsky scores, emergency-care use, LVEF, and functional class; exploratory endpoints compare one versus two treatments (Day 0 and Day 90) and analyze BNP as a predictor.
Hemostemix (OTCQB: HMTXF) filed an Institutional Review Board application on October 9, 2025 for a Phase 1 study titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)."
The open‑label, multi‑center protocol plans 20–100 adults (ages 50–100), intrathecal autologous ACP-01 delivery with an optional second dose at 3 months, and follow‑up at 3, 6, and 12 months. Primary endpoints are safety and feasibility; secondary endpoints include cognition tests, EEG BNA, and MRI perfusion.
Hemostemix (OTCQB: HMTXF) announced a non‑brokered private placement of up to $700,000 with a lead order of $330,000 on October 7, 2025. Units priced at $0.11 include one common share and one warrant exercisable at $0.15 for two years from closing.
Warrants include an accelerator: if the 10‑day weighted average closing price exceeds $0.185 after four months, expiry can be accelerated to 30 days after notice. A company director is participating, triggering related‑party disclosures; the company is relying on MI 61‑101 exemptions for valuation and minority approval. Proceeds are allocated to general working capital, including marketing and sales of VesCell™.
Hemostemix (OTCQB: HMTXF) has filed FDA Pre-IND Application 1517 for a basket protocol Phase I clinical trial of its lead therapy ACP-01 (VesCell™). The trial aims to evaluate safety, feasibility, and early efficacy of ACP-01 across multiple conditions including vascular dementia, peripheral arterial disease, angina, cardiomyopathy, and congestive heart failure.
The company plans to integrate real-world evidence from Florida, where ACP-01 is legally available under SB 1768, to support IND advancement and expedited regulatory designations. Hemostemix has completed 498 safe treatments to date and has 11 peer-reviewed publications demonstrating safety and efficacy.
Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, announced that CEO Thomas Smeenk will present at the Life Science Investor Forum on September 18, 2025, at 12:00 p.m. ET. The company's flagship product, VesCell™ (ACP-01), treats various cardiovascular conditions including peripheral arterial disease and chronic limb threatening ischemia.
The company has demonstrated strong clinical credentials with 498 successful treatments and 11 peer-reviewed publications confirming safety and efficacy. Following Florida Senate Bill 1768's passage, Hemostemix can now offer treatments to no-option patients in Florida, marking a significant milestone in commercialization.
Hemostemix (OTCQB: HMTXF) has announced the upcoming presentation of significant clinical data for its VesCell™ (ACP-01) therapy in treating severe angina. The study demonstrated remarkable improvements in patients with chronic stable angina who had exhausted traditional treatment options.
Key clinical findings include: 24% increase in six-minute walk distance (from 333.65 to 414.95 meters), 26% improvement in exercise capacity (from 5.62 to 7.09 METs), and a 45% reduction in heart muscle perfusion defects. The Canadian Cardiovascular Society angina score improved significantly from 2.1 to 1.05, indicating substantial pain relief.
The company plans to offer this treatment in Florida under SB 1768, using the revenue and real-world data to fund a future double-blind randomized clinical trial for global approval.
Hemostemix (OTCQB:HMTXF), a leading autologous stem cell therapy company, has received TSXV approval to settle CDN$400,000 of debt through the issuance of 2,000,000 common shares at $0.20 per share.
The Settlement Shares will be subject to a four-month statutory hold period and require TSXV acceptance. The company confirms this debt settlement will not create a new control person, and no finder's fees will be paid. Hemostemix offers VesCell™ (ACP-01) therapy in Florida under SB 1768 for various cardiovascular and ischemic conditions.